COMPANY PROFILE / #889
Genesis Molecular AI
Developer of artificial intelligence-driven drug discovery technology designed to accelerate the identification and development of small molecule medicines. The company's technology integrates generative AI models with computational chemistry and iterative, interdisciplinary research workflows to design, evaluate, and optimize small molecule drug that drives the discovery and development of novel molecule drugs to treat patients suffering from severe and debilitating diseases, enabling the medical community to upgrade and optimize patient clinical outcomes.Privately Held (backing)
已融资170
最新估值—
员工数—
成立年份Numerate, BioVision, X-37, Exscientia, NuMedii, Numerion Labs, Verge Analytics, BioBlocks, Sygnature Discovery, BPS Bioscience, Lysosomal Therapeutics, Yumanity Therapeutics, Owkin, Bionext, Alector, Berg, Cyclica, Personalis, Molecular Assemblies
公司概况
- Companies
- Genesis Molecular AI
- Description
- —
- Website
- San Mateo, CA
- HQ Location
- Developer of artificial intelligence-driven drug discovery technology designed to accelerate the identification and development of small molecule medicines. The company's technology integrates generative AI models with computational chemistry and iterative, interdisciplinary research workflows to design, evaluate, and optimize small molecule drug that drives the discovery and development of novel molecule drugs to treat patients suffering from severe and debilitating diseases, enabling the medical community to upgrade and optimize patient clinical outcomes.
- Year Founded
- Numerate, BioVision, X-37, Exscientia, NuMedii, Numerion Labs, Verge Analytics, BioBlocks, Sygnature Discovery, BPS Bioscience, Lysosomal Therapeutics, Yumanity Therapeutics, Owkin, Bionext, Alector, Berg, Cyclica, Personalis, Molecular Assemblies
- Keywords
- 2026: 170, 2025: 112, 2024: 91, 2023: 66 E, 2022: 40, 2021: 26 E, 2020: 12
- Competitors
- —
- Ownership Status
- Announced/In Progress
- Company Financing Status
- Privately Held (backing)
融资与估值
- Total Raised
- 170
- First Financing Date
- 14.10
- First Financing Size
- 3
- First Financing Valuation
- evan.feinberg@genesistherapeutics.ai
- Last Financing Date
- -1.27%
- Last Financing Deal Type
- 20-May-2026
- Last Financing Size
- Later Stage VC
- Last Financing Valuation
- —
- Last Financing Status
- —
- Last Known Valuation
- —
- Last Known Valuation Date
- Early Stage VC
- Last Known Valuation Deal Type
- 4.10
- Valuation Estimate
- 25-Aug-2023
- Valuation Estimate Growth Rate
- biotech platform, biotechnology company, computational platform, deep learning, drug discovery tool, drugs licence, neural networks research, small molecule
- Active Investors
- Venture Capital-Backed
- # Active Investors
- 34%
- Acquirers
- Alumni Ventures, Andreessen Horowitz, Baker Brothers Investments, BlackRock, Cultural Leadership Fund, Felicis, Fidelity Management & Research Company, Harpoon VC, JAZZ Venture Partners, Jeff Rothschild, Lilly USA, Mana Ventures, Mark Leslie, Menlo Ventures, NVentures (Santa Clara), Open Field Capital, Propagator Ventures, Radical Ventures, Rock Springs Capital, Society Health, T. Rowe Price Group, Ulu Ventures, Valera Capital
团队与联系人
- Employees
- —
- Employee Growth %
- 2019
- Employee History
- —
- Primary Contact
- 327.39
- Primary Contact Title
- +1 (203) 615-4567
- Primary Contact Email
- Evan Feinberg
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- 18.44%
- Growth Rate
- -8.94%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 603
- Size Multiple
- —
- Size Multiple % Change
- 424.03
- Size Multiple Change
- 0.00%
- Size Multiple Percentile
- 0.00x
- Majestic Referring Domains
- 20.22x
- SimilarWeb Unique Visitors
- -571
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- 1
- SimilarWeb Growth Rate Percentile
- 1,996
- Success Probability Over Time – 1 Year
- 60%
- Success Probability Over Time – 3 Year
- 70%
- Success Probability Over Time – 5 Year
- Co-Founder, Chief Executive Officer & Board Member
记录来源：public.companies · 原始序号 #889 · 所有字段均按数据库原值展示。